SCHEMBL3013304

SCHEMBL3013304

CCOc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(OC)cc4)CC3)n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.57
RAB9A P51151 5/20 0.57
MAPT P10636 9/20 0.56
NPC1 O15118 3/20 0.54
ALDH1A1 P00352 6/20 0.52
LMNA P02545 7/20 0.51
MAPK1 P28482 6/20 0.51
POLB P06746 2/20 0.47
MMP1 P03956 1/20 0.46
MMP3 P08254 1/20 0.46
MMP7 P09237 1/20 0.46
MMP9 P14780 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
USP2 O75604 3/20 0.46
HTT P42858 2/20 0.46
TP53 P04637 1/20 0.46
ALOX15 P16050 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
RECQL P46063 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2998857 0.93 SMN1; SMN2 (0.65) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL3020074 0.92 SMN1; SMN2 (0.53) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL2998418 0.91 SMN1; SMN2 (0.55) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL3007794 0.91 SMN1; SMN2 (0.52) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL3019741 0.91 MAPT (0.54) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL3006770 0.90 SMN1; SMN2 (0.57) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL3017446 0.90 SMN1; SMN2 (0.53) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL3002187 0.90 SMN1; SMN2 (0.46) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL3007302 0.90 SMN1; SMN2 (0.46) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL3011948 0.89 SMN1; SMN2 (0.60) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.